Compare SINT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | GDTC |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | 42 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 10.4M |
| IPO Year | 2007 | 2021 |
| Metric | SINT | GDTC |
|---|---|---|
| Price | $1.50 | $0.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 23.3K | 9.5K |
| Earning Date | 05-13-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,018,000.00 | N/A |
| Revenue This Year | $30.26 | N/A |
| Revenue Next Year | $413.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $0.68 |
| 52 Week High | $6.78 | $3.68 |
| Indicator | SINT | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 27.68 | 48.51 |
| Support Level | N/A | $0.99 |
| Resistance Level | $2.98 | $1.07 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 4.56 | 73.80 |
SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.